ArticleTranslational cancer research2021
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Genetic insights into lung squamous cell carcinoma: howTranslational cancer research · 2026Article
- Effect of chemotherapy on passenger mutations in metastatic colorectal cancer.Molecular oncology · 2026Article
- A succinylation-related prognostic model for predicting lung adenocarcinoma prognosis and guiding immunotherapy.Clinical proteomics · 2026Article
- Article
- Cancer detection via one-shot learning: integrating gene expression and genomic mutation analysis.BMC bioinformatics · 2025Article
- Identification of the clinical value and biological effects of TTN mutation in liver cancer.Molecular medicine reports · 2025Article
- Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden.Discover oncology · 2025Article
- Attenuated titin protein expression is associated with advanced stages of ovarian cancer.Molecular therapy. Oncology · 2025Article
- Machine learning integration with multi-omics data constructs a robust prognostic model and identifies PTGES3 as a therapeutic target for precision oncology in lung adenocarcinoma.Frontiers in immunology · 2025Article
- Article
- Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy.JCO precision oncology · 2024Article
- Multi-omics data analysis reveals the complex roles of age in differentiated thyroid cancer.Heliyon · 2024Article
- Article
- A novel hypergraph model for identifying and prioritizing personalized drivers in cancer.PLoS computational biology · 2024Article
- Article
- Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.Combinatorial chemistry & high throughput screening · 2024Article
- Titin as a potential novel therapeutic target in colorectal cancer.Journal of cellular and molecular medicine · 2023Article
- Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma.Journal of translational medicine · 2023Observational
- Necroptosis-Related Modification Patterns Depict the Tumor Microenvironment, Redox Stress Landscape, and Prognosis of Ovarian Cancer.Oxidative medicine and cellular longevity · 2023Article
- Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy is the preferred treatment in many types of cancer including lung cancer. However, most of patients resist chemotherapy resulting in disease progressive and recurrence. Titin (
methodsClinical information and related somatic mutation profiles were obtained from The Cancer Genome Atlas (TCGA) database and analyzed by R-Studio using R-package. Overall survival (OS) curve and the association between gene mutation and clinical features were determined by GraphPad 6.0 software.
resultsAvailable data including 563 lung adenocarcinoma (LUAD) and 505 LUSC subjects were included in this study. Among all patients, 205 out of 563 LUAD and 326 out of 505 LUSC patients displayed
conclusionsCollectively,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.